3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Breast
1
Conditions
Neoplasms
18
Breast Neoplasms
16
Lung Neoplasms
10
Carcinoma, Non-Small-Cell Lung
6
Prostatic Neoplasms
5
Melanoma
5
Colorectal Neoplasms
5
Brain Neoplasms
5
Pancreatic Neoplasms
4
Ovarian Neoplasms
4
Uterine Cervical Neoplasms
3
Triple Negative Breast Neoplasms
3
Skin Neoplasms
3
Myeloproliferative Disorders
3
Leukemia, Myeloid, Acute
3
Kidney Neoplasms
3
Head and Neck Neoplasms
3
Carcinoma, Hepatocellular
3
Recurrence
2
Neoplasm, Residual
2
Neoplasm Metastasis
2
Myelodysplastic Syndromes
2
Lymphoma, Non-Hodgkin
2
Lymphoma, B-Cell
2
Lung Diseases
2
Glioma
2
Glioblastoma
2
Genetic Predisposition to Disease
2
Esophageal Neoplasms
2
Endometrial Neoplasms
2
Interventions
Cyclophosphamide
17
fludarabine phosphate
12
pembrolizumab
11
Brentuximab Vedotin
11
Nivolumab
10
Mycophenolic Acid
10
fludarabine
9
Doxorubicin
9
Dacarbazine
9
Whole-Body Irradiation
8
Vinblastine
7
Magnetic Resonance Spectroscopy
7
Filgrastim
7
Etoposide
7
Cyclosporine
7
Specimen Handling
6
Sirolimus
5
Radiotherapy
5
Peripheral Blood Stem Cell Transplantation
5
Melphalan
5
Granulocyte Colony-Stimulating Factor
5
Busulfan
5
Tacrolimus
4
Gemcitabine
4
pegfilgrastim
3
Vinorelbine
3
Radiation
3
Cyclosporins
3
Carmustine
3
thymoglobulin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hodgkin Disease
×
Blood Specimen Collection
×
90 days
×
Clear all
NCT05595577
2026-03-20
PALS
Wake Forest University Health Sciences
Phase NA
Recruiting
110 enrolled